BRINGING CONTINUOUS DATA TO THERAPY MANAGEMENT
Injectsense exists at the intersection of advanced semiconductor technology and medical systems.
We develop implant-based digital health systems to provide medical staff with continuous long-term data for improved therapy management.
OUR DNA
Combining the Best of Microelectronics and Medical Devices
​
Injectsense stands apart from other device developers thanks to its deep roots in two worlds: semiconductor and medical systems. We combine years of hands-on engineering experience in advanced microtechnology -- including ultra-low power IC design, telemetry and miniaturization -- with medical market, regulatory, software, and device expertise.
Our cross-functional approach has bridged these domains, yielding a number of innovative patent-pending solutions. Our Silicon Valley technical team has years of design and fabrication experience in semiconductor, wireless communications, and wafer-scale volume manufacture, while our Twin Cities team brings decades of commercial medical system and software development.
Leadership
Ariel Cao
Co-founder
President & CEO
Ates Gurcan
VP Engineering
Kevin Berg
COO
Lead, Medical Systems
Cenk Acar
Co-founder
VP MEMS
Medical Advisory Board
OPHTHALMOLOGY
Iqbal "Ike" Ahmed, MD, FSCRC
Moran Eye Center
Jason Bacharach, MD FAAO
California Pacific Medical Center
Christophe Baudoin, MD
Institut de la Vision, Paris
Antoine Brezin, MD, Ph.D.
Paris Cite University
School of Medicine
Ernesto Collazo, MD, FAAO
Collazo Eye
John G. Flanagan, Ph.D. FAAO
Berkeley School of Optometry
.jpg)
Richard Lindstrom MD, FAAO
Minnesota Eye Consultants
David Richardson MD
San Marino Eye
Stephen Sinclair, MD FAAO
Sinclair Retinal Associates
Kuldev Singh, MD
Glaucoma Service
Stanford University
Arthur Sit, MD, FAAO
Mayo Clinic
Robert Stamper, MD
University of California
San Francisco
Charles Yancy, MD, Ph.D.
West Metro Ophthalmology
Myron Yanoff, MD, FAAO
Chair Emeritus Ophthalmology
Scheie Eye Institute
INVESTMENT
Partnering with Major Strategics
​
Injectsense partners with major strategics who understand that autonomous, continuous monitoring of key markers will change the standard of care and improve disease outcomes through evidence-supported therapies.
